{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:07:05Z","timestamp":1792786025727,"version":"4.5.0"},"reference-count":133,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"AstraZeneca K.K."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Type I interferons (IFNs) have recently received a lot of attention with the elucidation of the pathogenesis of systemic lupus erythematosus (SLE). Type I IFNs are associated with many SLE symptoms and play a role in the pathogenesis of autoimmune diseases that may occur concurrently with SLE, such as Sj\u00f6gren\u2019s syndrome, antiphospholipid syndrome, myositis, scleroderma, and interferonopathy. Type I IFNs could be the link between these diseases. However, direct measurement of type I IFN levels and the IFN gene signature is currently unavailable in clinical practice. This review discusses type I IFN signalling in SLE, investigates the role of type I IFN in the clinical manifestations and symptoms associated with SLE and other IFN-related diseases, and discusses the clinical tests that can be used to diagnose SLE and measure disease activity. In addition, the role of type I IFN\u2013blocking therapies as potential treatments for SLE is discussed.<\/jats:p>","DOI":"10.1093\/mr\/roac140","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T06:30:27Z","timestamp":1669617027000},"page":"857-867","source":"Crossref","is-referenced-by-count":57,"title":["Interferons and systemic lupus erythematosus: Pathogenesis, clinical features, and treatments in interferon-driven disease"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health , Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kusuda","sequence":"additional","affiliation":[{"name":"Medical, AstraZeneca K.K. , Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Medical, AstraZeneca K.K. , Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"key":"2023082610105438700_R1","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nm.2752","article-title":"Taming lupus\u2014a new understanding of pathogenesis is leading to clinical advances","volume":"18","author":"Liu","year":"2012","journal-title":"Nat Med"},{"key":"2023082610105438700_R2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","article-title":"Autoimmunity and organ damage in systemic lupus erythematosus","volume":"21","author":"Tsokos","year":"2020","journal-title":"Nat Immunol"},{"key":"2023082610105438700_R3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/1756-185X.13817","article-title":"State-of-the-art treatment of systemic lupus erythematosus","volume":"23","author":"Tanaka","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"2023082610105438700_R4","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/rheumatology\/kex260","article-title":"The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies","volume":"56","author":"Rees","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2023082610105438700_R5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/BOR.0000000000000480","article-title":"Epidemiology of systemic lupus erythematosus: an update","volume":"30","author":"Stojan","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"2023082610105438700_R6","doi-asserted-by":"crossref","first-page":"i55","DOI":"10.1093\/rheumatology\/kew427","article-title":"Pathways leading to an immunological disease: systemic lupus erythematosus","volume":"56","author":"Zharkova","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2023082610105438700_R7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102615","article-title":"Clinical disease activity and flare in SLE: current concepts and novel biomarkers","volume":"119","author":"Thanou","year":"2021","journal-title":"J Autoimmun"},{"key":"2023082610105438700_R8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/acr.24431","article-title":"Systemic lupus erythematosus: targeted literature review of the epidemiology, current treatment, and disease burden in the Asia Pacific region","volume":"74","author":"Tanaka","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023082610105438700_R9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.autrev.2010.08.016","article-title":"Systemic lupus erythematosus: clinical presentations","volume":"10","author":"Smith","year":"2010","journal-title":"Autoimmun Rev"},{"key":"2023082610105438700_R10","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023082610105438700_R11","doi-asserted-by":"crossref","DOI":"10.3390\/cells8090963","article-title":"Signaling pathways of type I and type III interferons and targeted therapies in systemic lupus erythematosus","volume":"8","author":"Chyuan","year":"2019","journal-title":"Cells"},{"key":"2023082610105438700_R12","first-page":"21","article-title":"The importance of the type I interferon system in autoimmunity","volume":"34","author":"R\u00f6nnblom","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2023082610105438700_R13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/08916930903510872","article-title":"Type I interferons in systemic autoimmunity","volume":"43","author":"Sozzani","year":"2010","journal-title":"Autoimmunity"},{"key":"2023082610105438700_R14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00299","article-title":"Interferon-\u03b1 subtypes as an adjunct therapeutic approach for human immunodeficiency virus functional cure","volume":"9","author":"George","year":"2018","journal-title":"Front Immunol"},{"key":"2023082610105438700_R15","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000270","article-title":"Interferon pathway in SLE: one key to unlocking the mystery of the disease","volume":"6","author":"R\u00f6nnblom","year":"2019","journal-title":"Lupus Sci Med"},{"key":"2023082610105438700_R16","article-title":"Development of potential pharmacodynamic and diagnostic markers for anti-IFN-\u03b1 monoclonal antibody trials in systemic lupus erythematosus","volume":"2009","author":"Yao","year":"2009","journal-title":"Hum Genomics Proteomics"},{"key":"2023082610105438700_R17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.trsl.2014.10.005","article-title":"Targeting of type I interferon in systemic autoimmune diseases","volume":"165","author":"Crow","year":"2015","journal-title":"Transl Res"},{"key":"2023082610105438700_R18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"2023082610105438700_R19","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155633","article-title":"Abnormalities of the type I interferon signaling pathway in lupus autoimmunity","volume":"146","author":"Gallucci","year":"2021","journal-title":"Cytokine"},{"key":"2023082610105438700_R20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041414","article-title":"Constitutive phosphorylation of interferon receptor A-associated signaling proteins in systemic lupus erythematosus","volume":"7","author":"Ram\u00edrez-V\u00e9lez","year":"2012","journal-title":"PLoS One"},{"key":"2023082610105438700_R21","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1093\/rheumatology\/keaa187","article-title":"Elevated STAT1 expression but not phosphorylation in lupus B cells correlates with disease activity and increased plasmablast susceptibility","volume":"59","author":"Aue","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2023082610105438700_R22","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144918","article-title":"Bite of the wolf: innate immune responses propagate autoimmunity in lupus","volume":"131","author":"Gupta","year":"2021","journal-title":"J Clin Invest"},{"key":"2023082610105438700_R23","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1177\/0961203319885447","article-title":"Type I interferon gene signature test-low and -high patients with systemic lupus erythematosus have distinct gene expression signatures","volume":"28","author":"Brohawn","year":"2019","journal-title":"Lupus"},{"key":"2023082610105438700_R24","doi-asserted-by":"crossref","DOI":"10.1186\/ar2887","article-title":"Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFN\u03b1 antibody, in systemic lupus erythematosus","volume":"12","author":"Yao","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2023082610105438700_R25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12519-019-00229-3","article-title":"Immunological pathogenesis and treatment of systemic lupus erythematosus","volume":"16","author":"Pan","year":"2020","journal-title":"World J Pediatr"},{"key":"2023082610105438700_R26","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (SLE)","volume":"20","author":"M\u00f6ckel","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2023082610105438700_R27","doi-asserted-by":"crossref","first-page":"v12","DOI":"10.1093\/rheumatology\/keaa484","article-title":"New biomarkers in SLE: from bench to bedside","volume":"59","author":"Capecchi","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2023082610105438700_R28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1600-065X.2008.00625.x","article-title":"BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?","volume":"223","author":"Ramanujam","year":"2008","journal-title":"Immunol Rev"},{"key":"2023082610105438700_R29","article-title":"B cell therapy in systemic lupus erythematosus: from rationale to clinical practice","volume":"7","author":"Parodis","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"2023082610105438700_R30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00427","article-title":"Plasma cell differentiation pathways in systemic lupus erythematosus","volume":"9","author":"Malkiel","year":"2018","journal-title":"Front Immunol"},{"key":"2023082610105438700_R31","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/art.41532","article-title":"Type I interferon-activated STAT4 regulation of follicular helper T cell-dependent cytokine and immunoglobulin production in lupus","volume":"73","author":"Dong","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2023082610105438700_R32","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/icb.2012.10","article-title":"Role of type I interferons in the activation of autoreactive B cells","volume":"90","author":"Kiefer","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"2023082610105438700_R33","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/ni829","article-title":"DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL","volume":"3","author":"Litinskiy","year":"2002","journal-title":"Nat Immunol"},{"key":"2023082610105438700_R34","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000286","article-title":"Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE","volume":"5","author":"Casey","year":"2018","journal-title":"Lupus Sci Med"},{"key":"2023082610105438700_R35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/BOR.0000000000000770","article-title":"Immunopathogenesis of skin injury in systemic lupus erythematosus","volume":"33","author":"Hile","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"2023082610105438700_R36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jid.2021.07.161","article-title":"IFN-1s: sentinels shaping distinct immune responses in skin","volume":"142","author":"Garzorz-Stark","year":"2022","journal-title":"J Invest Dermatol"},{"key":"2023082610105438700_R37","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1136\/annrheumdis-2018-213197","article-title":"Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa","volume":"77","author":"Sarkar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023082610105438700_R38","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/B978-0-323-47927-1.00033-5","volume-title":"Dubois\u2019 Lupus Erythematosus and Related Syndromes","author":"Chong","year":"2019","edition":"9th"},{"key":"2023082610105438700_R39","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/exd.12708","article-title":"Genome-wide association study identifies new susceptibility loci for cutaneous lupus erythematosus","volume":"24","author":"Kunz","year":"2015","journal-title":"Exp Dermatol"},{"key":"2023082610105438700_R40","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1684\/ejd.2014.2421","article-title":"Exacerbation of alopecia areata during pegylated interferon alpha-2b and ribavirin therapy, possibly due to the collapse of hair follicle immune privilege","volume":"24","author":"Ito","year":"2014","journal-title":"Eur J Dermatol"},{"key":"2023082610105438700_R41","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/1120009X.2016.1245235","article-title":"Alopecia universalis as a side effect of pegylated interferon \u03b1-ribavirin combination therapy for hepatitis C: a rare case report","volume":"29","author":"Verma","year":"2017","journal-title":"J Chemother"},{"key":"2023082610105438700_R42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2133.2010.09775.x","article-title":"Type 1 interferon signature in the scalp lesions of alopecia areata","volume":"163","author":"Ghoreishi","year":"2010","journal-title":"Br J Dermatol"},{"key":"2023082610105438700_R43","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1590\/abd1806-4841.20153881","article-title":"Systemic lupus erythematosus and Raynaud\u2019s phenomenon","volume":"90","author":"Heimovski","year":"2015","journal-title":"An Bras Dermatol"},{"key":"2023082610105438700_R44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/sarh.2002.34606","article-title":"Interferon-induced Raynaud\u2019s syndrome","volume":"32","author":"Schapira","year":"2002","journal-title":"Semin Arthritis Rheum"},{"key":"2023082610105438700_R45","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.clineuro.2013.09.027","article-title":"Interferons beta have vasoconstrictive and procoagulant effects: a woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis","volume":"115","author":"Rot","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"key":"2023082610105438700_R46","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1046\/j.1365-2249.1999.00842.x","article-title":"Increased interferon-gamma (IFN-gamma) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud\u2019s phenomenon","volume":"116","author":"Molteni","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"2023082610105438700_R47","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/art.23186","article-title":"Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18","volume":"58","author":"Tucci","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2023082610105438700_R48","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3899\/jrheum.210391","article-title":"High systemic type I interferon activity is associated with active class III\/IV lupus nephritis","volume":"49","author":"Iwamoto","year":"2022","journal-title":"J Rheumatol"},{"key":"2023082610105438700_R49","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023082610105438700_R50","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1002\/art.22044","article-title":"Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus","volume":"54","author":"Feng","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2023082610105438700_R51","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2023082610105438700_R52","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/ard.2008.093146","article-title":"Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus","volume":"68","author":"Landolt-Marticorena","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023082610105438700_R53","first-page":"68","article-title":"Imaging of joints in systemic lupus erythematosus","volume":"36","author":"Tani","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2023082610105438700_R54","first-page":"485","article-title":"The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review","volume":"55","author":"Zayat","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2023082610105438700_R55","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/art.22578","article-title":"Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus","volume":"56","author":"Nzeusseu Toukap","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2023082610105438700_R56","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cei.13585","article-title":"Arthritis in systemic lupus erythematosus is characterized by local IL-17A and IL-6 expression in synovial fluid","volume":"205","author":"Sippl","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"2023082610105438700_R57","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1182\/blood-2007-05-089086","article-title":"Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis","volume":"110","author":"Denny","year":"2007","journal-title":"Blood"},{"key":"2023082610105438700_R58","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/rheumatology\/keu431","article-title":"Interleukin 10 hampers endothelial cell differentiation and enhances the effects of interferon \u03b1 on lupus endothelial cell progenitors","volume":"54","author":"Cates","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2023082610105438700_R59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037000","article-title":"Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients","volume":"7","author":"Somers","year":"2012","journal-title":"PLoS One"},{"key":"2023082610105438700_R60","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/art.1780350410","article-title":"Interferon-alpha in lupus psychosis","volume":"35","author":"Shiozawa","year":"1992","journal-title":"Arthritis Rheum"},{"key":"2023082610105438700_R61","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1985-9","article-title":"Interferon-\u03b1 exacerbates neuropsychiatric phenotypes in lupus-prone mice","volume":"21","author":"Zeng","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2023082610105438700_R62","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrneurol.2014.148","article-title":"Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers","volume":"10","author":"Jeltsch-David","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"2023082610105438700_R63","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/ana.25908","article-title":"Absence of neuronal autoantibodies in neuropsychiatric systemic lupus erythematosus","volume":"88","author":"Varley","year":"2020","journal-title":"Ann Neurol"},{"key":"2023082610105438700_R64","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3899\/jrheum.110983","article-title":"Utility of interferon-\u03b1 as a biomarker in central neuropsychiatric involvement in systemic lupus erythematosus","volume":"39","author":"Fragoso-Loyo","year":"2012","journal-title":"J Rheumatol"},{"key":"2023082610105438700_R65","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1878-y","article-title":"High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus","volume":"21","author":"Oke","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2023082610105438700_R66","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jneuroim.2010.03.018","article-title":"Endogenous type-I interferon activity is not associated with depression or fatigue in systemic lupus erythematosus","volume":"223","author":"Kellner","year":"2010","journal-title":"J Neuroimmunol"},{"key":"2023082610105438700_R67","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102374","article-title":"Inflammatory markers in systemic lupus erythematosus","volume":"110","author":"Aringer","year":"2020","journal-title":"J Autoimmun"},{"key":"2023082610105438700_R68","doi-asserted-by":"crossref","first-page":"366","DOI":"10.5414\/CNP67366","article-title":"Anemia associated with pegylated interferon-alpha2a and alpha2b therapy in hemodialysis patients","volume":"67","author":"Espinosa","year":"2007","journal-title":"Clin Nephrol"},{"key":"2023082610105438700_R69","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/gast.2002.34175","article-title":"Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha","volume":"123","author":"Peck-Radosavljevic","year":"2002","journal-title":"Gastroenterology"},{"key":"2023082610105438700_R70","doi-asserted-by":"crossref","DOI":"10.1186\/ar2475","article-title":"Interferon-induced protein IFIT4 is associated with systemic lupus erythematosus and promotes differentiation of monocytes into dendritic cell-like cells","volume":"10","author":"Huang","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"2023082610105438700_R71","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12016-020-08798-2","article-title":"Type I interferons in the pathogenesis and treatment of autoimmune diseases","volume":"59","author":"Jiang","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"2023082610105438700_R72","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1136\/annrheumdis-2019-215571","article-title":"Ultrasensitive serum interferon-\u03b1 quantification during SLE remission identifies patients at risk for relapse","volume":"78","author":"Mathian","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023082610105438700_R73","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/rheumatology\/keu020","article-title":"Limited effectiveness for the therapeutic blockade of interferon \u03b1 in systemic lupus erythematosus: a possible role for type III interferons","volume":"54","author":"Amezcua-Guerra","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2023082610105438700_R74","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1136\/annrheumdis-2015-208140","article-title":"Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification","volume":"75","author":"Munroe","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2023082610105438700_R75","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000625","article-title":"Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis","volume":"9","author":"Northcott","year":"2022","journal-title":"Lupus Sci Med"},{"key":"2023082610105438700_R76","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.trsl.2021.07.006","article-title":"Cluster of highly expressed interferon-stimulated genes associate more with African ancestry than disease activity in patients with systemic lupus erythematosus. A systematic review of cross-sectional studies","volume":"238","author":"Siddiqi","year":"2021","journal-title":"Transl Res"},{"key":"2023082610105438700_R77","article-title":"Interferon gene signature expression and serological differences in Japanese and non-Japanese SLE patients","author":"Kohsaka"},{"key":"2023082610105438700_R78","doi-asserted-by":"crossref","first-page":"157","DOI":"10.6061\/clinics\/2012(02)11","article-title":"Clinical and serological manifestations associated with interferon-\u03b1 levels in childhood-onset systemic lupus erythematosus","volume":"67","author":"Postal","year":"2012","journal-title":"Clinics (Sao Paulo)"},{"key":"2023082610105438700_R79","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1136\/ard.2004.033753","article-title":"Type I interferon correlates with serological and clinical manifestations of SLE","volume":"64","author":"Dall\u2019era","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2023082610105438700_R80","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/annrheumdis-2021-221835","article-title":"Serum interferon-\u03b1 levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity","volume":"81","author":"Chasset","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023082610105438700_R81","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.688753","article-title":"Comparison of surrogate markers of the type I interferon response and their ability to mirror disease activity in systemic lupus erythematosus","volume":"12","author":"Enocsson","year":"2021","journal-title":"Front Immunol"},{"key":"2023082610105438700_R82","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1177\/0961203309105529","article-title":"Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus","volume":"18","author":"Petri","year":"2009","journal-title":"Lupus"},{"key":"2023082610105438700_R83","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/art.39950","article-title":"Gene expression and pharmacodynamic changes in 1,760 systemic lupus erythematosus patients from two phase III trials of BAFF blockade with tabalumab","volume":"69","author":"Hoffman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2023082610105438700_R84","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-20203-9","article-title":"Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus","volume":"8","author":"Connelly","year":"2018","journal-title":"Sci Rep"},{"key":"2023082610105438700_R85","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02414-0","article-title":"The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus","volume":"23","author":"Mai","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2023082610105438700_R86","article-title":"Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus","volume":"10","author":"Smith","year":"2020","journal-title":"Sci Rep"},{"key":"2023082610105438700_R87","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.3748\/wjg.14.5508","article-title":"Treatment of severe steroid refractory ulcerative colitis","volume":"14","author":"Van Assche","year":"2008","journal-title":"World J Gastroenterol"},{"key":"2023082610105438700_R88","doi-asserted-by":"crossref","DOI":"10.1186\/ar2763","article-title":"Flow cytometry analysis of glucocorticoid receptor expression and binding in steroid-sensitive and steroid-resistant patients with systemic lupus erythematosus","volume":"11","author":"Du","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2023082610105438700_R89","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2665-9913(21)00006-0","article-title":"Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: a cross-sectional and in-vitro study","volume":"3","author":"Northcott","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2023082610105438700_R90","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.24091","article-title":"Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus","volume":"61","author":"Hersh","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2023082610105438700_R91","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0961203313519157","article-title":"Simultaneous changes in serum HMGB1 and IFN-\u03b1 levels and in LAIR-1 expression on plasmatoid dendritic cells of patients with juvenile SLE. New therapeutic options?","volume":"23","author":"Kanakoudi-Tsakalidou","year":"2014","journal-title":"Lupus"},{"key":"2023082610105438700_R92","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02161-8","article-title":"Higher interferon score and normal complement levels may identify a distinct clinical subset in children with systemic lupus erythematosus","volume":"22","author":"Tesser","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2023082610105438700_R93","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/art.41072","article-title":"Differential responsiveness of monocyte and macrophage subsets to interferon","volume":"72","author":"Han","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2023082610105438700_R94","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000080","article-title":"Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE","volume":"2","author":"Kennedy","year":"2015","journal-title":"Lupus Sci Med"},{"key":"2023082610105438700_R95","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1177\/0961203319868531","article-title":"Autoantibodies in SLE: prediction and the p value matrix","volume":"28","author":"Choi","year":"2019","journal-title":"Lupus"},{"key":"2023082610105438700_R96","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/08916930400022715","article-title":"Anti-Sm and anti-RNP antibodies","volume":"38","author":"Migliorini","year":"2005","journal-title":"Autoimmunity"},{"key":"2023082610105438700_R97","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1002\/art.27700","article-title":"Anti-U1 RNP antibodies in cerebrospinal fluid are associated with central neuropsychiatric manifestations in systemic lupus erythematosus and mixed connective tissue disease","volume":"62","author":"Sato","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2023082610105438700_R98","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/annrheumdis-2021-221662","article-title":"Anti-RNP antibodies are associated with the interferon gene signature but not decreased complement levels in SLE","volume":"81","author":"Hubbard","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023082610105438700_R99","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00296-018-4059-4","article-title":"The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease","volume":"38","author":"Dima","year":"2018","journal-title":"Rheumatol Int"},{"key":"2023082610105438700_R100","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10067-008-1043-5","article-title":"Anti-Ro antibody and cutaneous vasculitis in systemic lupus erythematosus","volume":"28","author":"Fukuda","year":"2009","journal-title":"Clin Rheumatol"},{"key":"2023082610105438700_R101","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s10067-015-2941-y","article-title":"Clinical associations of anti-Smith antibodies in PROFILE: a multi-ethnic lupus cohort","volume":"34","author":"Arroyo-\u00c1vila","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2023082610105438700_R102","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1874312901711010113","article-title":"SLE and serum complement: causative, concomitant or coincidental?","volume":"11","author":"Sandhu","year":"2017","journal-title":"Open Rheumatol J"},{"key":"2023082610105438700_R103","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/0961203308089694","article-title":"Increased expression of the type I interferon-inducible gene, lymphocyte antigen 6 complex locus E, in peripheral blood cells is predictive of lupus activity in a large cohort of Chinese lupus patients","volume":"17","author":"Tang","year":"2008","journal-title":"Lupus"},{"key":"2023082610105438700_R104","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/OARRR.S167783","article-title":"Sj\u00f6gren\u2019s syndrome and systemic lupus erythematosus: links and risks","volume":"11","author":"Pasoto","year":"2019","journal-title":"Open Access Rheumatol"},{"key":"2023082610105438700_R105","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3899\/jrheum.190250","article-title":"Sj\u00f6gren syndrome in systemic lupus erythematosus: a subset characterized by a systemic inflammatory state","volume":"47","author":"Ruacho","year":"2020","journal-title":"J Rheumatol"},{"key":"2023082610105438700_R106","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1136\/ard.46.8.580","article-title":"HLA class I and II, interferon, interleukin 2, and the interleukin 2 receptor expression on labial biopsy specimens from patients with Sj\u00f6gren\u2019s syndrome","volume":"46","author":"Rowe","year":"1987","journal-title":"Ann Rheum Dis"},{"key":"2023082610105438700_R107","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/art.21006","article-title":"Gene expression profiling of minor salivary glands clearly distinguishes primary Sj\u00f6gren\u2019s syndrome patients from healthy control subjects","volume":"52","author":"Hjelmervik","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2023082610105438700_R108","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/rheumatology\/kex490","article-title":"Systemic interferon type I and type II signatures in primary Sj\u00f6gren\u2019s syndrome reveal differences in biological disease activity","volume":"57","author":"Bodewes","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2023082610105438700_R109","first-page":"185","article-title":"Type I interferon signature in Sj\u00f6gren\u2019s syndrome: pathophysiological and clinical implications","volume":"37","author":"Marketos","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2023082610105438700_R110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00487","article-title":"Type I interferon signature in primary antiphospholipid syndrome: clinical and laboratory associations","volume":"10","author":"Palli","year":"2019","journal-title":"Front Immunol"},{"key":"2023082610105438700_R111","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/jth.14427","article-title":"Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation","volume":"17","author":"Hisada","year":"2019","journal-title":"J Thromb Haemost"},{"key":"2023082610105438700_R112","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2019.108265","article-title":"Independent association of low IFN\u03bb1 gene expression and type I IFN score\/IFN\u03bb1 ratio with obstetric manifestations and triple antiphospholipid antibody positivity in primary antiphospholipid syndrome","volume":"209","author":"Flessa","year":"2019","journal-title":"Clin Immunol"},{"key":"2023082610105438700_R113","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.autrev.2018.11.004","article-title":"Enhanced type I interferon gene signature in primary antiphospholipid syndrome: association with earlier disease onset and preeclampsia","volume":"18","author":"Ugolini-Lopes","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2023082610105438700_R114","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1177\/09612033221101731","article-title":"Association between interferon-I producing plasmacytoid dendritic cells and thrombotic antiphospholipid syndrome","volume":"31","author":"Rosa Dos Santos","year":"2022","journal-title":"Lupus"},{"key":"2023082610105438700_R115","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/sji.12449","article-title":"Autoantibody specificities and type I interferon pathway activation in idiopathic inflammatory myopathies","volume":"84","author":"Ekholm","year":"2016","journal-title":"Scand J Immunol"},{"key":"2023082610105438700_R116","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"2023082610105438700_R117","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.12955","article-title":"The role of interferons type I, II and III in myositis: a review","volume":"31","author":"Bolko","year":"2021","journal-title":"Brain Pathol"},{"key":"2023082610105438700_R118","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2023082610105438700_R119","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clim.2012.03.005","article-title":"Emerging therapies for systemic lupus erythematosus \u2014focus on targeting interferon-alpha","volume":"143","author":"Lichtman","year":"2012","journal-title":"Clin Immunol"},{"key":"2023082610105438700_R120","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40744-020-00212-9","article-title":"Systemic lupus erythematosus (SLE) therapy: the old and the new","volume":"7","author":"Basta","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2023082610105438700_R121","article-title":"What\u2019s new in the treatment of systemic lupus erythematosus","volume":"8","author":"Liossis","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2023082610105438700_R122","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8142368","article-title":"Biologics in the treatment of lupus erythematosus: a critical literature review","volume":"2019","author":"Samotij","year":"2019","journal-title":"Biomed Res Int"},{"key":"2023082610105438700_R123","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/14397595.2019.1583832","article-title":"Safety and tolerability of sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in Japanese patients with systemic lupus erythematosus: a multicenter, phase 2, open-label study","volume":"30","author":"Takeuchi","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2023082610105438700_R124","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2023082610105438700_R125","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/19420862.2015.1007810","article-title":"Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-\u03b1 receptor 1 antibody","volume":"7","author":"Peng","year":"2015","journal-title":"MAbs"},{"key":"2023082610105438700_R126","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/14397595.2019.1583833","article-title":"Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: a multicenter, phase 2, open-label study","volume":"30","author":"Tanaka","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2023082610105438700_R127","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2023082610105438700_R128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"2023082610105438700_R129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2020.1812201","article-title":"Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials","volume":"31","author":"Tanaka","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2023082610105438700_R130","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2023082610105438700_R131","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/annrheumdis-2021-221425","article-title":"Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials","volume":"81","author":"Vital","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023082610105438700_R132","article-title":"Long Term Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus (TULIP SLE LTE)","author":"Clinicaltrials.gov","year":"2022"},{"key":"2023082610105438700_R133","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1136\/ard-2022-222549","article-title":"Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-\u03b1","volume":"81","author":"Mathian","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac140\/47997921\/roac140.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/5\/857\/51269884\/roac140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/5\/857\/51269884\/roac140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T06:13:04Z","timestamp":1693030384000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/5\/857\/6849474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":133,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,11,28]]},"published-print":{"date-parts":[[2023,8,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac140","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2022,11,28]]}}}